Related Experiment Video
Updated: Jun 11, 2025
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
6.1K
[Advances in hemophilia treatment]
1Department of Pediatrics, Nara Medical University.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|October 2, 2024
Summary
Recent advancements in hemophilia treatment, including extended half-life clotting factors and gene therapy, aim to overcome challenges like frequent administration and inhibitor development, improving patient quality of life.
Area of Science:
- Hematology
- Pharmacology
- Gene Therapy
Background:
- Replacement therapy with clotting factor (F) VIII or FIX has improved quality of life (QOL) for hemophilia patients.
- Frequent intravenous administration, blood access issues, and inhibitor development remain significant challenges.
Purpose of the Study:
- To review recent advancements in hemophilia treatment addressing existing challenges.
- To highlight novel therapies and their potential impact on patient QOL.
Main Methods:
- Review of clinical studies and drug development in hemophilia treatment.
- Focus on extended half-life products, non-clotting factor therapies, and gene therapy.
Main Results:
- Introduction of extended half-life clotting factor products and non-clotting factor therapies.
- Development of anti-FIX/FX bispecific antibodies, anti-antithrombin therapy, and anti-TFPI monoclonal antibodies.
- Gene therapy approval in the U.S. and Europe with improved protein expression.
Conclusions:
- Novel therapies like bispecific antibodies and gene therapy offer improved QOL for hemophilia patients.
- These developments are expected to overcome long-standing treatment problems.
- Further improvements in hemophilia management and patient outcomes are anticipated.
More Related Videos
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
636
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
636
01:29Venous Thrombosis III: Interprofessional Care
3
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
3
01:24Disorders of Hemostasis
738
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
738
01:20Extrinsic and Intrinsic Pathways of Hemostasis
6.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
6.3K
01:05Introduction to Hemostasis
6.4K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
6.4K
01:30Venous Thrombosis IV: Nursing Management
3
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
3